Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Adult female patients \>/=18 years of age
Metastatic HER2 positive breast cancer
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Disease progression during or following trastuzumab-based therapy for 1st line metastatic breast cancer (trastuzumab must have been part of the last prior treatment regimen)
Prior treatment with taxane-containing regimen
Left ventricular ejection fraction (LVEF) \>/=50 percent
For women of childbearing potential agreement to use highly effective non-hormonal form of contraception or two effective forms of non-hormonal contraception by patient and/or partner. Contraception must continue for duration of study treatment and for at least 6 months after last dose of study drug treatment
You may not be if
Prior treatment with pertuzumab or capecitabine
Concurrent treatment with other experimental drug
Concurrent immunotherapy or anticancer hormonal therapy
Serious concurrent disease (e.g. active infection, uncontrolled hypertension, cardiovascular disease)
Central nervous system (CNS) metastases, which are not well controlled
History of exposure to anthracycline cumulative dose equivalent to 360mg/m2
History of congestive heart failure of any New York Heart Association criteria, or serious cardiac arrhythmia requiring treatment
History of myocardial infarction within 6 months prior to randomization
History of LVEF decline to below 50% during or after prior trastuzumab therapy or other cardiac toxicity during previous trastuzumab treatment that necessitated discontinuation of trastuzumab
History of another cancer which could affect compliance or result interpretation
Inadequate organ function
Pregnant or breastfeeding women
life expectancy \< 12 weeks
Clareo Health | A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)
